Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 11/20 | 0.36 |
| ▸ | PPARD | Q03181 | 3/20 | 0.34 |
| ▸ | PPARA | Q07869 | 3/20 | 0.34 |
| ▸ | PPARG | P37231 | 2/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.31 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2339518 | 0.93 | REN (0.37) | RENPPARDPPARAPPARGGRM5 | |
| SCHEMBL4583012 | 0.93 | REN (0.37) | RENPPARDPPARAPPARGGRM5 | |
| SCHEMBL1039086 | 0.93 | REN (0.35) | RENPPARDPPARAPPARGGRM5 | |
| SCHEMBL3914348 | 0.93 | REN (0.38) | RENGRM5 | |
| SCHEMBL3907496 | 0.93 | REN (0.38) | RENGRM5 | |
| SCHEMBL4582351 | 0.92 | REN (0.34) | RENPPARDPPARAPPARGHRH3 | |
| SCHEMBL1040011 | 0.92 | PDE4B (0.37) | RENPPARDPPARAPPARG | |
| SCHEMBL4582354 | 0.92 | REN (0.34) | RENPPARDPPARAPPARGHRH3 | |
| SCHEMBL1077522 | 0.92 | REN (0.35) | RENPPARDPPARAPPARGGRM5 | |
| SCHEMBL4583362 | 0.92 | REN (0.34) | RENPPARDPPARAPPARGHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325947-A1 | NITRATE ESTERS OF PIPERIDINES | NOVARTIS AG (CH) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325947-A1 | NITRATE ESTERS OF PIPERIDINES | NOS2, NOS1, NOS3 | REN 29/4885PPARD 625/4885PPARA 1115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.